Israel Englander Denali Therapeutics Inc. Transaction History

Millennium Management LLC

$199 Billion
Q3 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Millennium Management LLC holds 60,168 shares of DNLI stock, worth $1.29 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

60,168

Previous 619,929 90.29%

Holding current value

$1.29 Million

Previous $14.4 Million 87.83%

% of portfolio

0.0%

Previous 0.01%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$20.96 - $31.05 $11.7 Million - $17.4 Million	-559,761 Reduced 90.29%	60,168 $1.75 Million
Q2 2024 Aug 14, 2024	BUY	$14.96 - $23.22 $3.43 Million - $5.32 Million	229,313 Added 58.71%	619,929 $14.4 Million
Q1 2024 May 15, 2024	BUY	$15.83 - $23.35 $6.18 Million - $9.12 Million	390,616 New	390,616 $8.02 Million
Q2 2023 Aug 14, 2023	BUY	$23.37 - $32.96 $2.15 Million - $3.03 Million	91,897 Added 23.79%	478,186 $14.1 Million
Q1 2023 May 15, 2023	BUY	$21.91 - $32.67 $1.95 Million - $2.91 Million	89,196 Added 30.02%	386,289 $8.9 Million
Q4 2022 Feb 14, 2023	SELL	$26.28 - $33.92 $5.23 Million - $6.75 Million	-199,091 Reduced 40.12%	297,093 $8.26 Million
Q3 2022 Nov 14, 2022	SELL	$25.97 - $38.53 $3.87 Million - $5.75 Million	-149,152 Reduced 23.11%	496,184 $15.2 Million
Q2 2022 Aug 15, 2022	BUY	$20.88 - $35.19 $13.5 Million - $22.7 Million	645,336 New	645,336 $19 Million
Q1 2022 May 16, 2022	SELL	$29.0 - $47.27 $532,440 - $867,877	-18,360 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$42.59 - $55.02 $1 Million - $1.29 Million	-23,482 Reduced 56.12%	18,360 $819,000
Q3 2021 Nov 15, 2021	BUY	$48.48 - $78.23 $1.09 Million - $1.75 Million	22,399 Added 115.2%	41,842 $2.11 Million
Q2 2021 Aug 16, 2021	BUY	$50.3 - $78.44 $237,969 - $371,099	4,731 Added 32.16%	19,443 $1.53 Million
Q1 2021 May 17, 2021	BUY	$53.8 - $81.53 $478,712 - $725,453	8,898 Added 153.04%	14,712 $840,000
Q4 2020 Feb 16, 2021	SELL	$36.89 - $93.56 $4.5 Million - $11.4 Million	-121,874 Reduced 95.45%	5,814 $487,000
Q3 2020 Nov 16, 2020	BUY	$23.13 - $38.84 $2.44 Million - $4.09 Million	105,379 Added 472.36%	127,688 $4.58 Million
Q2 2020 Aug 14, 2020	BUY	$16.01 - $28.82 $357,167 - $642,945	22,309 New	22,309 $539,000
Q4 2019 Feb 14, 2020	SELL	$14.4 - $19.99 $1.46 Million - $2.03 Million	-101,659 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$15.32 - $21.92 $1.56 Million - $2.23 Million	101,659 New	101,659 $1.56 Million
Q2 2019 Aug 14, 2019	SELL	$18.5 - $28.14 $637,343 - $969,451	-34,451 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$17.99 - $24.65 $619,773 - $849,217	34,451 New	34,451 $800,000
Q3 2018 Nov 14, 2018	SELL	$12.46 - $21.74 $2.14 Million - $3.74 Million	-171,979 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$15.25 - $21.02 $2.62 Million - $3.61 Million	171,979 New	171,979 $2.62 Million
Q1 2018 May 15, 2018	SELL	$15.36 - $24.8 $1.45 Million - $2.34 Million	-94,316 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$15.04 - $21.45 $1.42 Million - $2.02 Million	94,316	94,316 $1.48 Million

Others Institutions Holding DNLI

# of Institutions

227

Shares Held

119M

Call Options Held

60.6K

Put Options Held

48.4K

View Full List

About Denali Therapeutics Inc.

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $2.88B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

More about DNLI

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account